Full Text View
Tabular View
No Study Results Posted
Related Studies
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
This study is ongoing, but not recruiting participants.
Study NCT00025506   Information provided by National Cancer Institute (NCI)

First Received on October 11, 2001.   Last Updated on January 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Recurrent Uterine Sarcoma
Uterine Carcinosarcoma
Additional conditions recognized in this trial
Carcinosarcoma
Mixed Tumor, Mullerian
Sarcoma
Uterine Neoplasms
More general conditions related to this trial
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Connective and Soft Tissue
Urogenital Neoplasms
Uterine Diseases
Interventions listed in this trial
thalidomide
laboratory biomarker analysis
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services